AlzeCure Pharma logo

Loading..
Svenska
Svenska
  • About us
    About us
      • AlzeCure Pharma in brief
      • Mission, vision & strategy
      • A word from the CEO
      • Organization
        • Management team
        • Board of directors
        • Founders
        • Scientific advisors
        • Collaborations and Partnership
      • History
      • Career
        • Open positions
  • Research & development
    Research & development
      • Project portfolio
      • NeuroRestore
      • Alzstatin
      • Alzheimer’s disease
      • Painless
        • ACD440
        • TrkA-NAM
      • Pain
      • Small molecules
      • Publications
  • Governance
    Governance
      • Corporate Governance Reports
      • General meeting
        • General meetings
      • Nomination Committee
      • Board of directors
      • Management team
      • Remuneration
      • Auditors
      • Articles of association
  • Investors
    Investors
      • Capital Markets Day 2023
      • AlzeCure Pharma on First North Premier Growth Market
        • Certified Adviser
      • Prospectuses
        • Rights Issue December 2022
        • Rights Issue 2022
        • Listing prospectus 2018
      • The share
        • Trading information
        • Sharecapital development
        • Dividend policy
        • Ownership structure
        • Insiders
        • Analyst Coverage
      • Financial reports
      • Financial calendar
      • Presentations and Interviews
      • Subscribe
      • Contact
  • Media
    Media
      • Press releases
      • Presentations and Interviews
      • Video gallery
      • Image bank
        • Board of directors
        • Management
        • Founders
        • Logotype
      • Financial calendar
      • Subscribe
      • Contact
  • Contact
    Contact
      • Office
      • Investors
      • Media

Press releases

All pressreleases
  • Regulatory press releases
  • Other press releases
2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • All years
November 28, 2023

AlzeCure presents at DNB Nordic-American Healthcare Conference in New York December 6-7

November 22, 2023

AlzeCure presents at Stora Aktiedagarna on November 27

November 9, 2023

AlzeCure publishes its interim report for January – September 2023

November 2, 2023

AlzeCure presents at Redeye Life Science Day on November 23

October 25, 2023

AlzeCure presents disease-modifying data with NeuroRestore ACD856 at Alzheimer’s conference CTAD

October 19, 2023

AlzeCure’s Alzheimer project NeuroRestore ACD856 is also granted a patent in Japan

October 17, 2023

AlzeCure publishes new article on the GSM mechanism behind Alzstatin against Alzheimer’s disease

October 12, 2023

AlzeCure presents clinical phase II-data with ACD440 for neuropathic pain at pain conference

October 3, 2023

AlzeCure presents at Redeye Neurology Theme Event on October 11

September 26, 2023

AlzeCure gets presentation accepted on disease-modifying effects of ACD856 at Alzheimer’s conference

September 20, 2023

AlzeCure presents positive phase II clinical data with ACD440 against neuropathic pain at EFIC 2023 Conference

September 18, 2023

AlzeCure gets an abstract on phase II clinical data with ACD440 for neuropathic pain accepted at pain conference

August 24, 2023

AlzeCure publishes its interim report for January – June 2023

August 9, 2023

AlzeCure publishes the positive clinical results from the phase I trial of NeuroRestore ACD856 against Alzheimer’s

July 11, 2023

AlzeCure publishes new disease modifying data with NeuroRestore ACD856 against Alzheimer’s and cognitive disorders

July 3, 2023

New article on antidepressive effects with NeuroRestore ACD856

June 13, 2023

New article on disease modifying data with NeuroRestore ACD856 against Alzheimer’s now available online

June 8, 2023

AlzeCure presents at Aktiespararna’s Småbolagsdagarna on June 13

May 24, 2023

AlzeCure announces positive Phase IIa clinical study data in neuropathic pain with the non-opioid ACD440

May 23, 2023

AlzeCure AlzeCure presents at Redeye Growth Day on June 1

May 22, 2023

AlzeCure is granted European patent for NeuroRestore ACD856

May 19, 2023

Dr. Janet Hoogstraate new board member of AlzeCure Pharma

May 17, 2023

Report from the annual general meeting of AlzeCure Pharma on 17 May 2023

May 16, 2023

AlzeCure participates at Penser Market on May 25

May 11, 2023

AlzeCure holds a Capital Markets Day on May 17

May 4, 2023

AlzeCure publishes its interim report for January – March 2023

April 19, 2023

AlzeCure gets an abstract on non-opioid ACD440 for neuropathic pain accepted at the EFIC 2023 Conference

April 5, 2023

AlzeCure Pharma publishes its Annual Report for 2022

March 30, 2023

AlzeCure presents new data at Alzheimer’s conference AD/PD on the potential disease-modifying effect of NeuroRestore ACD856

March 28, 2023

AlzeCure presents new data on its preventive treatment Alzstatin at the Alzheimer’s conference AD/PD 2023

March 13, 2023

AlzeCure achieves Last Patient Last Visit (LPLV) in its phase II clinical trial of the non-opioid ACD440 in neuropathic pain

March 7, 2023

AlzeCure participates at Redeye Alzheimer Seminar on March 15

February 24, 2023

AlzeCure publishes its Year-end report for January – December 2022

January 31, 2023

Last patient included in AlzeCure’s Phase II clinical trial in peripheral neuropathic pain with the non-opioid ACD440

January 11, 2023

AlzeCure selects CD and enters next development phase with Alzstatin ACD680 against Alzheimer’s

January 10, 2023

The rights issue is registered and the trading in Paid Subscription Shares ceases

  • Media
    • Press releases
    • Presentations and Interviews
    • Video gallery
    • Image bank
      • Board of directors
      • Management
      • Founders
      • Logotype
    • Financial calendar
    • Subscribe
    • Contact
Mikael Widell
Mikael Widell
Head of Communications and IR
[email protected]
+46 703 11 99 60
About us
  • AlzeCure Pharma in brief
  • Mission, Vision & Strategy
  • A word from the CEO
  • Organization
  • Career
  • History
Research & development
  • Project portfolio
  • NeuroRestore
  • Alzstatin
  • Alzheimer’s disease
  • Painless
  • Pain
  • Small molecules
  • Publications
Governance
  • Corporate Governance Reports
  • General meeting
  • Nomination Committee
  • Board of directors
  • Management team
  • Remuneration
  • Auditors
  • Articles of association
Investors
  • Capital Markets Day 2023
  • AlzeCure Pharma on First North Premier Growth Market
  • The share
  • Financial reports
  • Financial calendar
  • Presentations and Interviews
  • Subscribe
  • Contact
Media
  • Press releases
  • Presentations and Interviews
  • Video gallery
  • Image bank
  • Financial calendar
  • Subscribe
  • Contact
Contact
  • Office
  • Investors
  • Media

AlzeCure Pharma AB, Hälsovägen 7,  SE-141 57 Huddinge, Sweden. Registration number: 559094-8302.

  • Follow us on LinkedIn
  • About cookies
  • Privacy policy for Alzecure Pharma